Gene Therapy Technologies, Markets and Companies Analysis & Projections to 2026PR Newswire (press release)The estimates are based on epidemiology of diseases to be treated with gene therapy, the portion of those who will be eligible for these treat… Continue reading
Gene Therapy Technologies, Markets and Companies Analysis & Projections to 2026PR Newswire (press release)The estimates are based on epidemiology of diseases to be treated with gene therapy, the portion of those who will be eligible for these treat… Continue reading
EurekAlert (press release)Does brain tissue regeneration depend on maturity of stem cells used for transplantation?EurekAlert (press release)New Rochelle, NY, September 13, 2017–New research has shown that the success of transplanting stem cells into … Continue reading
Listening In on Lung CellsHarvard Medical School (registration)To investigate lung cell formation, Kim and her former postdoctoral researcher Joo-Hyeon Lee, who is now at the Cambridge Stem Cell Institute and the Wellcome Trust in the U.K., observed wh… Continue reading
Labiotech.eu (blog) |
Swiss Biotech’s Immunotherapy for Brain Cancer gets Orphan Drug Designation
Labiotech.eu (blog) The FDA will give special treatment to Vaximm’s oral T cell immunotherapy for glioma, which is particularly difficult to treat. Vaximm focuses on the development of oral T cell immunotherapies for cancers. The FDA and European Commission have given … |
Singularity Hub |
FDA Breaks New Ground With First Approved Gene Therapy for Cancer
Singularity Hub Co-developed with the drug giant Novartis, the therapy, CAR–T, genetically alters a patient’s own immune cells to target and destroy cancer cells. Recently, in a historic decision, the FDA threw their support behind Kymriah (tisagenlecleucel), a … |
Singularity Hub |
FDA Breaks New Ground With First Approved Gene Therapy for Cancer
Singularity Hub Co-developed with the drug giant Novartis, the therapy, CAR–T, genetically alters a patient’s own immune cells to target and destroy cancer cells. Recently, in a historic decision, the FDA threw their support behind Kymriah (tisagenlecleucel), a … |
OncLive |
Pseudoprogression on Immunotherapy in HNSCC
OncLive If we think about immunotherapies, we will often give the patient the drug. If the tumor grows and they’re tolerating it, we may say, “Oh, sometimes the tumor gets bigger before it gets smaller,” which has not been reported very much in head and neck … |